We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.28B
AUM Growth
-$1.41B
Cap. Flow
-$1.19B
Cap. Flow %
-22.61%
Top 10 Hldgs %
53.54%
Holding
466
New
23
Increased
24
Reduced
24
Closed
360

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$72.5M
2
LEGN icon
Legend Biotech
LEGN
+$64.3M
3
OSCR icon
Oscar Health
OSCR
+$64.1M
4
DVAX
Dynavax Technologies
DVAX
+$62.6M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$39M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$187M
2
KURA icon
Kura Oncology
KURA
+$106M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$66.5M
4
SGRY icon
Surgery Partners
SGRY
+$57.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$56.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Industrials 0.23%
3 Consumer Staples 0.01%
4 Energy 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
176
Cencora
COR
$62.2B
– –
-3,485
Closed -$784K
COST icon
177
Costco
COST
$429B
– –
-945
Closed -$838K
CRGX
178
DELISTED
CARGO Therapeutics
CRGX
– –
-23,078
Closed -$426K
CRI icon
179
Carter's
CRI
$1.45B
– –
-8,867
Closed -$576K
CRL icon
180
Charles River Laboratories
CRL
$11.6B
– –
-2,204
Closed -$434K
CRM icon
181
Salesforce
CRM
$149B
– –
-2,806
Closed -$768K
CRMT icon
182
America's Car Mart
CRMT
$27.1M
– –
-5,979
Closed -$251K
CRS icon
183
Carpenter Technology
CRS
$27.8B
– –
-5,864
Closed -$936K
CRVL icon
184
CorVel
CRVL
$3.14B
– –
-2,952
Closed -$322K
CRWD icon
185
CrowdStrike
CRWD
$185B
– –
-6,784
Closed -$476K
CSTL icon
186
Castle Biosciences
CSTL
$725M
– –
-16,943
Closed -$483K
CTKB icon
187
Cytek Biosciences
CTKB
$576M
– –
-17,586
Closed -$97.4K
CUBE icon
188
CubeSmart
CUBE
$9.62B
– –
-5,550
Closed -$299K
CVBF icon
189
CVB Financial
CVBF
$4.02B
– –
-23,802
Closed -$424K
CVS icon
190
CVS Health
CVS
$140B
– –
-874,800
Closed -$55M
CXM icon
191
Sprinklr
CXM
$1.48B
– –
-55,785
Closed -$431K
CYRX icon
192
CryoPort
CYRX
$765M
– –
-68,143
Closed -$553K
CYTK icon
193
Cytokinetics
CYTK
$10.8B
– –
-12,884
Closed -$680K
DAR icon
194
Darling Ingredients
DAR
$9.28B
– –
-20,072
Closed -$746K
DBRG icon
195
DigitalBridge
DBRG
$2.93B
– –
-64,839
Closed -$916K
DDD icon
196
3D Systems Corp
DDD
$412M
– –
-56,349
Closed -$160K
DE icon
197
Deere & Co
DE
$173B
– –
-2,051
Closed -$856K
DFIN icon
198
Donnelley Financial Solutions
DFIN
$1.31B
– –
-24,968
Closed -$1.64M
DG icon
199
Dollar General
DG
$27.8B
– –
-10,132
Closed -$857K
DH icon
200
Definitive Healthcare
DH
$74.6M
– –
-73,387
Closed -$328K
6 7
8
9 10

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2024 Portfolio in Review

As of Q4 2024, Deerfield Management held 466 positions worth $5.28B, down 21% from $6.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $1.19B in Q4 2024, closing 360 positions and reducing 24 holdings. Its most notable exit was Kura Oncology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Legend Biotech worth $50.5M.

  • Deerfield Management's largest Q4 2024 buy was Legend Biotech: 1,551,718 shares worth $50.5M.
  • Deerfield Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $72.5M increase.
  • Deerfield Management's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $187M.
  • Deerfield Management fully exited Kura Oncology in Q4 2024, selling an estimated $106M.
  • Deerfield Management's ten largest holdings make up 54% of its $5.28B portfolio in Q4 2024.
  • Deerfield Management opened 23 new positions and closed 360 in Q4 2024.
  • Deerfield Management's portfolio value fell 21% quarter-over-quarter to $5.28B.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.